Topical Effectiveness of Molgramostim (GM-CSF) in Sickle Cell Leg Ulcers
- 29 March 2004
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 208 (2) , 135-137
- https://doi.org/10.1159/000076487
Abstract
Background: Leg ulcers are a frequently neglected, severe complication of sickle cell disease (SCD), responsible for significant altering quality of life. The management of leg ulcers remains disappointing. Local application of recombinant human granulocyte-macrophage colony-stimulating factor has been shown to be effective in several types of chronic wound healing. Methods: We report 5 homozygous sickle cell patients with 14 leg ulcers lasting from 1 month to 6 years, treated with topical dripping of molgramostim solution. Results: Healing was obtained for 9/14 ulcers, with no local or systemic adverse reactions. Comments: Molgramostim solution appears to be an adequate therapy for SCD leg ulcers but a more conclusive evaluation will depend on larger series of patients and other types of formulations for topical applications could be even more effective in the future.Keywords
This publication has 2 references indexed in Scilit:
- Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcersThe American Journal of Surgery, 1997
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994